AcelRx to resubmit NDA in 2015
September 26, 2014 at 13:52 PM EDT
AcelRx Pharmaceuticals Inc. (Nasdaq:
ACRX) will resubmit its New Drug Application for Zalviso in the first
quarter of 2015. The stock price tumbled $1.23 to $5.49.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|